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ABSTRACT
Though nanotechnology which exploits the use of nanoparticles for therapeutic application
have embarked as an emerging tool for drug delivery applications, the delivery of therapeutic
molecules into deep ocular compartments has always been a challenging task. In this regard,
the main objective of our current investigation was to develop and evaluate the fluocinolone
acetonide (FA) loaded nanostructure lipid carrier (FA-NLC) in situ gel for improved ocular
bioavailability by subconjunctival injection. FA, a corticosteroid administered for inhibiting
the ocular inflammation either as intravitreal injection or as intravitreal implants. The FANLCs were developed by using vitamin A palmitate as one of the lipid components, to get an
additional advantage in dry eye reduction which is caused by vitamin A deficiency. FA-NLCs
were evaluated for physicochemical characteristics (size, polydispersity index and charge),
release and stability studies. Further, in situ gel of FA-NLC was developed using gellan gum
and hydroxypropyl methylcellulose as gelling agents. In situ gels were characterized for
rheological behavior, in vitro release and permeability studies using corneal and scleral
tissues. Furthermore, the ocular pharmacokinetic studies of in situ gel were conducted in New
Zealand albino rabbits after subconjunctival injection, and compared with control
formulation. Differential scanning calorimetry and Fourier-Transform Infrared Spectroscopy
(FTIR) studies revealed no interaction between the drug and lipid phase and also reduction of
the FA crystallinity in the NLC. FA-NLC (FN2b) showed 159.1 ± 3.8 nm of size, 0.150 ±
0.05 of polydispersity index, -8.4 ± 0.4 of surface charge, 96.53 ± 2.4 of assay and 95.43 ±
2.89 % as entrapment efficiency, respectively. In situ gel prepared with gellan gum showed
excellent rheological properties, sustained drug release and significant permeability compared
with control formulation. FA-NLC and in situ gel was found to be stable for 30 days at room
ii

and 4oC temperature. The in vivo studies revealed high drug concentration in the posterior
section of the eye owing to high bioavailability of the drug to ocular tissues.
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LIST OF ABBREVIATIONS AND SYMBOLS
ACN Acetonitrile
AH

Aqueous humor

BSS

Balanced salt solution

DME Diabetic macular edema
DPBS Dulbecco’s phosphate buffer saline
EE

Entrapment Efficiency

FA

Fluocinolone acetonide

HPMC Hydroxypropyl methylcellulose
IC

Iris-ciliary

IPBS Isotonic phosphate buffer saline
NLCs Nanosized lipid carriers
PDI

Polydispersity index

RC

Retinal choroid

THF

Tetrahydrofuran

VH

Vitreous humor

ZP

Zeta potential
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CHAPTER I
INTRODUCTION

The eye consists of complex anatomical and physiological barriers thereby making it
a complicated organ for the delivery of therapeutic molecules across the ocular
compartments. On this regard, lipid nanocarriers due to their diverse physical and structural
properties help in the delivery of therapeutics across several ocular compartments. The
complex ocular microenvironment makes eye resistant to various extraneous entities.[1]
Cornea which forms the outermost part of the eye functions as one of the primary obstacles
for drug permeability into ocular milieu. Apart from the physiological structure and reduced
permeability, poor pre-corneal volume, and residence time contribute to the diminished
bioavailability (less than 5%) of the ocular therapeutics.[2]–[4]
Topical delivery is the most accessed methods for the treatment of ocular diseases and
nanotechnology, which exploits the use of nanoparticles has shown a great promise in
transporting molecules to various tissue compartments. Delivering drug molecules via
nanoparticulate systems like liposomes, lipid nanoparticles and nanoemulsions in the form of
eye drops, solution or suspension, gels, lotions or ointments are the most opted ways to
administer both hydrophilic and lipophilic drugs.[3], [5]–[8] Lipid nanoparticles are drug
nanospheres that are shelled in biodegradable lipids. With the size ranging from 40 to 1000
nanometers, lipid nanoparticles demonstrate a promising vehicle in drug permeability into the
ocular tissues. Along with the nanoparticulate system, inclusion of permeability enhancer,
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viscosity enhancer, or in situ gelling agent are considered to be the prime approach to subdue
the low precorneal residence time.
Vitamin A is a fat-soluble retinoid, plays a key role in the vision. An aldehyde
derivative of vitamin A is the precursor for rhodopsin, a glycoprotein pigment component of
rod cells presents in the retina. Deficiency in vitamin A causes ocular disorders such as dry
eyes and keratoconjunctivitis and investigations have shown that 0.05% of vitamin A
palmitate in the form of eye drops are efficacious for the treatment of dry eye disorder and
this was the motivation behind the use of Vitamin A palmitate as one of the lipids to
formulate our NLC system.[9]–[11]
In situ gels are viscous fluids which forms pliant translucent gels by the influence of
body pH, temperature, the presence of electrolytes or by photolytic interactions. As the
formulation gels only after its application, in situ gel provide enhanced drug delivery similar
to ointments or creams.[5], [12], [13] Gellan gum an anionic polysaccharide obtained from
Pseudomonas elodea, transforms from solution to gel in the presence of cations. Tear which
comprises of cations like sodium and potassium, facilitates the formation of double helix
cross-linking in gellan gum, thus increasing viscosity to form the gel.[13], [14]
Hydroxypropyl methylcellulose (HPMC) is a thermos-sensitive nonionic polysaccharide, that
forms a transparent viscous gel in contact with the tear fluid. The gelling of the polymer is
due to the formation of the hydrogen bonding with mucin. Therefore, addition of HPMC to
the formulation not only provides bio-adhesion but also increases the viscosity of the
formulation.[13], [15], [16] However, due to limitations of topical formulations like tear
turnover, constant drug dilation and impediment endowed by the corneas results in the sub
therapeutic ocular drug levels.
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Subconjunctival injections are introduced into the conjunctival layer surpassing the
lipid bulbar layer which hinders the drug penetration via the corneal route. After injecting,
drug penetration follows the trans scleral route, thus releasing a higher amount of the drug to
the posterior section of the eye. Due to depot formation in the conjunctival layer, this route
delivers a greater edge for the drug concentration in the ocular tissues compared to topical
formulations. Thus, subconjunctival injection extend to provide advantage over local drug
delivery with limited intricacy compared to intravitreal administration.[1], [3]
Diabetic macular edema (DME) which is one of the adverse effects of diabetes,
induces the expansion of the fluid in the retinal section. This fluid buildup causes damage to
the blood vessels and causes the macula to swell which initially deforms the vision and can
eventually lead to irreversible blindness. Studies have shown the use fluocinolone acetonide
(FA), a corticosteroid for the inhibiting the ocular inflammation caused by edema, blood
vessel dilation, fibrin disposition, cell or capillary proliferation or by collagen accumulation.
Currently, FA is administered as the intravitreal injection or as intravitreal implants for the
treatment of such inflammations.[17]–[19]
Hence, in the current study we attempted to develop a novel fluocinolone acetonide
loaded nanostructured lipid carriers (FA-NLC) in situ gels using vitamin A palmitate. The
physicochemical characteristics like particle size, charge, polydispersity index, assay and
entrapment were studied. Furthermore, the gelling characteristics like viscosity with and
without inclusion of simulated tear fluid, gelling time and gel intact time, firmness, and work
of adhesion were investigated for in situ gel formulation. The optimized formulation was
evaluated for the drug release, in vitro tissue permeation, tear kinetics and drug content in the
ocular tissues by administering the in situ gel formulation via subconjunctival route in the
New Zealand male albino rabbits compared with control formulation.
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CHAPTER II
METHODOLOGY

Materials
Fluocinolone acetonide, vitamin A palmitate, sesame oil, capmul PG-8, tween 80, and
hydroxypropyl methylcellulose (HPMC) were acquired from Fischer Scientific (Hampton,
NH, USA). Compritol 888 ATO (glyceryl behenate) was procured from Gattefossé (Paramus,
NJ, USA). Gellan gum was purchased from MP Biomedicals, LLC (Santa Ana, CA, USA).
Other entities required for the study like amicon ultra centrifugal filters (lined with 100 kDa
cellulose membrane), high-performance liquid chromatography (HPLC) grade, and liquid
chromatography mass spectroscopy (LCMS) optima grade solvents, and other analytical
grade chemicals were obtained from Fisher Scientific (Hampton, NH, USA).

Animal and animal tissues
Complete eye globules of male albino New Zealand rabbits were acquired from PelFreez Biologicals (Rogers, AR, USA). Male albino New Zealand rabbits, weighing 2 to 3 kg
were procured from Envigo (Indianapolis, IN, USA). All the in vivo studies were carried out
in accordance with the University of Mississippi Institutional Animal Care and Use
committee approved protocols (Protocol # 17-018).
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Preparation of FA-NLC and in situ gels
Selection of lipids
Lipids were screened on the basis of the relative drug affinity towards them. About 5
mg of drug was added to 10 mL of water in glass vials. To these approx., 1 g of lipid was
added, and the vials were kept in shaking water bath at 75oC for 24 h. The solubility of the
drug was later measured by precipitating out the lipid in methanol, followed by centrifugation
for 15 minutes (AccuSpin 17R centrifuge, Fisher Scientiﬁc, USA) at 13,000 rpm and
analyzing the drug in methanol using HPLC method.[20]

Selection of surfactants
Drug solubility was carried out in the categories of surfactants based on their HLB
values. For this purpose, about 5mg of FA was added to 10 mL of different 5% surfactant
solutions and was kept at 34oC with continuous shaking. Later the samples were centrifuged
with AccuSpin 17R centrifuge (Fisher Scientiﬁc, USA) at 13,000 rpm for 15 min and the
supernatant was diluted with methanol and analyzed using HPLC method. The surfactant
screening was performed on the basis of the solubility of the drug on various surfactants.[20]

Preparation of FA-NLC
Hot melt homogenization coupled with probe sonication technique was utilized to
prepare FA-NLCs.[21] The proportion of the drug and all the excipients for different trials
were provided in Table 1. The quantity of lipids and surfactants for the formulation were
determined based on different ratios taking one factor at a time. The lipid phase which
constitutes of Compritol 888 ATO and vitamin A palmitate as solid lipids and sesame oil as
liquid lipid, were melted together at 80oC. FA was added to this liquefied lipid with steady
5

magnetic stirring until a homogenous mixture was obtained. Later, capmul PG-8 was added
to this homogenous mixture. In a separate vial, aqueous phase comprising of deionized water
and tween 80 was heated to 80oC. On attaining the constant temperature, the aqueous phase
was added to the apparent lipid with constant stirring to get pre-emulsion. This mixture was
homogenized at high speed with T25 digital Ultra-Turrax for 5 min at 12000 rpm. The
homogenized mixture was then imposed to probe sonicator for 5 min at 40% amplitude with
15 sec pulse and 15 sec resting time to get desired nanoparticles. The pH of the formulations
was analyzed using pH meter (Mettler Toledo, USA).
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Table 1: Composition of fluocinolone acetonide loaded nanostructure lipid carriers

F and N indicate fluocinolone acetonide and NLC respectively. Each formulation contains 10
mg of drug and were prepared for 10 mL.

Fluocinolone acetonide in situ gels were prepared in the similar fashion as specified
above (using optimized FA-NLC formulation). The gelling agents, gellan gum, and HPMC
were added to aqueous phase and homogenizing the two phases.

HPLC Chromatographic conditions
The drug content in the samples was analyzed by means of High-Performance Liquid
Chromatography (HPLC) using Waters 717 plus autosampler, 600 Waters controller pump,
Waters 2487 ultraviolet (UV) dual absorbance detector and Agilent 3395 integrator. The
column used for analysis was C18 Luna ® 4.6mm x 250 mm and mobile phase comprised of
acetonitrile (ACN), water and tetrahydrofuran (THF) in the ratio of 77:13:10, respectively.
The detection wavelength (λmax) was set at 238 nm with the flow rate of mobile phase at 0.8
mL/min. All the samples were analyzed in triplicates for each study.[22]
7

Characterization of NLC
Measurement of particle size, polydispersity index (PDI) and zeta potential (ZP)
All the prepared NLC formulations were evaluated for particle size, zeta potential
(ZP) and PDI in triplicate, using a Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.,
MA, USA) by photon correlation spectroscopy at 25°C and with 173° backscatter detection
in clear, disposable folded capillary cells. The results for the particle size and PDI were
acquired based on volume displacement at 633 nm using a helium-neon laser. The samples
were diluted with doubled distilled 0.2µ filtered water in the ratio of 1:500.
Assay and entrapment efficiency
The assay of the FA-NLC and in situ formulation was quantified by lipid precipitation
method. About 100 µL of the formulation was added to 900 µL of mobile phase (77:13:10 of
ACN: Water: THF) and vortexed to precipitate out the lipid. Later, the samples were
centrifuged for 15 min at 13,000 rpm and the supernatant was analyzed for the drug content
using HPLC method.
Entrapment efficiency (EE) of the FA-NLC formulations was determined by
analyzing the free drug in the filtrate collected after centrifuging the formulation through
amicon ultra centrifugal filters for 15 min at 5000 rpm. Drug analysis was done by HPLC
method as discussed earlier. The entrapment efficiency (%) of FA was calculated using the
equation mentioned below.

%𝑬𝑬 =

(𝑾𝒇 − 𝑾𝒊) ∗ 𝟏𝟎𝟎
𝑾𝒊

Where, Wi is the theoretical weight of the drug in formulation and
Wf is the total free drug in the filtrate.
8

Differential scanning calorimetry (DSC)
The purity and interaction of the drug with other lipid components was determined by
subjecting to DSC analysis. DSC of pure FA and the lipid phase of the formulation including
drug were obtained by DSC 250 (TA instruments, USA). Approx. 5 mg of solid samples were
hermetically sealed in the T0 aluminium pans and scanned from 0 to 320 °C with the heating
rate of 10°C/min with constant nitrogen purging.

Fourier transform infrared spectroscopy (FTIR)
The FT-IR spectra of pure drug (FA), excipients and the physical mixture of the lipid
phase was evaluated utilizing Cary 660 series FTIR (Agilent Technologies, Place, Country)
and MIRacle ATR (attenuated total reflectance) systems to investigate the interactions of the
excipient on the drug.

Characterization of FA-NLC in situ gel
Rheological and in vitro gelling characteristics
In situ gelling agents in the formulation includes gellan gum alone and combination of
gellan gum with HPMC. The viscosity of the FA-NLC formulations and in situ gels was
determined using Brookfield cone and plate viscometer (LV-DV-II+ Pro Viscometer,
Middleboro, USA). The distance between the cone spindle and sampler cup was maintained
to the minimum and the temperature of the system was set to 34 ± 0.2 °C. Later
approximately 500 µL of sample was added to the cup and viscosity of the sample was
evaluated at different shear stress using CPE 52 spindle. The viscosity of the gel formulations
was also determined with simulated tear fluid (STF) with the ratio of 50:7 of the formulation
to STF so as to mimic the viscosity of the formulation after application into the eye.
9

Simulated tear fluid with pH of 7.0 ± 0.2 consists 0.678 g of NaCl, 0.0084 g of CaCl2·2H2O,
0.138 g of KCl, and 0.218 g of NaHCO3 in 100 mL of deionized water.[23] The viscosities
were registered from the Rheocalc software.
Gelling formation and gel residence time
Gel formation time of the in situ formulation was determined by placing approx. 50
µL of the formulation in a vial containing 10 mL of freshly prepared STF and visibly
checking the time taken by the formulation to gel in the fluid. Gel residence time was the
total time of the formulation resides intact within the STF. Approximately 50 µL the
formulation was added to the 10 mL of freshly prepared STF and the vial was kept at 34 ±
0.2°C with constant stirring. Time was recorded when the gel was breaking down or no
longer remained intact.

Gel firmness and adhesion
TA XT2i texture analyzer (Texture Technologies Corp. NY. USA) was utilized to
measure the gel firmness and work of adhesion for the optimized in situ gel formulation. At
the room temperature, the gel formulation was mixed with freshly prepared STF in ratio 50:7
was held on soft matter holder (TA-275). The measurement was done by compression mode
where 1-inch cylinder acrylic probe was embedded to the distance of 1 mm into the gel
formed with the speed of 0.5 mm/sec and 5 g of the triggering force.

Measurement of turbidimetry
FA-NLCs and in situ gels were examined for the percent transmittance (%T) at the
wavelength (λmax) of 520 nm using UV Genesys 6 (Thermo Fischer Scientific, USA) to
check visible transparency.[13] The turbidity of the formulations was measured over a period
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of 6 h after placing the formulation in STF in the ratio of 50:7 of formulation to tear fluid.
%T was calculated using the following formula:
𝑨 = 𝟐 − 𝒍𝒐𝒈 (%𝑻)
Where, A is absorbance of the sample when compared with deionized water.

In vitro release study
The release kinetics for the FA-NLCs and in situ gels were evaluated by adding 200
µL of the formulation to 10 mL of isotonic phosphate buffer saline (IPBS) (pH 7.4) with 5%
methyl β cyclodextrin. The temperature of the vials was maintained 34 ± 0.2 °C with
continuous magnetic stirring for 4 h. Approx. 1 mL of the aliquot was withdrawn at
predetermined time points and was replaced with equal volume receiver medium. The
samples were analyzed for the amount of drug by HPLC method.

Stability studies
The formulations were placed at 4oC and 25oC for weeks to assess their stability
during storage. Samples from the formulations were withdrawn at predetermined time point
and were evaluated for their particle size, PDI, surface charge, EE and assay as specified
earlier. About, 3 mL of the formulations, both NLCs and in situ gels were taken in the glass
vials and placed in the autoclave (AMSCO Scientific Model SI-120, USA) for pressure
controlled sterilization at 121°C for the time period of 60 min at 15 psi pressure. The
formulations were examined for their physical characteristics compared to the formulation of
before sterilization.
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In vitro permeation studies
Post-development of the FA-NLC and corresponding in situ gel, the formulations
were examined for their permeation release in the ocular tissues. The in vitro permeation
studies were carried out on corneal and scleral tissues. Whole rabbit eyes were bought
overnight from Pel-Freez Biologicals in Hanks balanced salt solution. The permeation study
was performed immediately after receiving the eyes. The tissues were separated and were
washed within ice-cold Dulbecco’s phosphate buffer saline (DPBS) solution with pH 7.4 and
later were mounted in between the donor and receiver on valia-chein diffusion cells
(PermeGear, Inc®, USA) with the epithelial tissue section towards the donor compartment of
the cell.
The receiver medium constituted of balanced salt solution (BSS) (pH 7.4) with 5%
methyl-β- cyclodextrin. The temperature of the cells was maintained at 34 ± 0.2°C and the
receiver was under continuous magnetic stirring throughout the experiment of 3 h. Approx.
200 µL of the formulation along with 50 µL of DPBS was added to the donor compartment
for the formation of sol-gel. The control used for the study was fluocinolone acetonide (0.1%)
suspended in deionized water containing gellan gum (0.3%) and HPMC (0.5%). About 600
µL of aliquots were pipetted out of the receiver cells and was replaced with equal volume
receiver medium. The samples were analyzed for the concentration of drug by HPLC method.
From the concentration; cumulative concentration, steady-state flux, and tissue
permeability were estimated. The equations for calculating cumulative concentration was
𝒙=𝒏

𝑴𝒏 = 𝑽𝒓 𝑪𝒓(𝒏) + ∑ 𝑽𝒔(𝒙−𝟏) 𝑪𝒓(𝒙−𝟏)
𝒙=𝟏
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Where, n is the number of sampling time point; Vr (mL) is the volume in the receiver cell and
VS (mL) is the volume of the sample collected on time points. Cr(n) (µg/mL) is the drug
concentration in the receiver chamber medium at the nth time point.
Flux is the rate of drug permeated through the tissue membrane per area of the tissue.
The calculation of the flux was determined from the slope of the cumulative drug permeation
versus time plot. The equation for calculating flux was:
𝑭𝒍𝒖𝒙(𝑱) = (𝒅𝑴/𝒅𝒕)/𝑨
Where, M is the cumulative amount of drug transported and A is the surface area of the tissue
(0.636 cm2)
The equation to determine the tissue permeability was:

𝑷𝒆𝒓𝒎𝒆𝒂𝒃𝒊𝒍𝒊𝒕𝒚 (𝑷𝒂𝒑𝒑) =

𝑺𝒕𝒆𝒂𝒅𝒚 𝒔𝒕𝒂𝒕𝒆 𝒇𝒍𝒖𝒙 (𝑱)
𝑫𝒐𝒏𝒐𝒓 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏

In vivo tear kinetics and distribution studies
In vivo studies were conducted in New Zealand male albino rabbits. Before the study,
the animals were kept for acclimatization up to 7 days with absolute access to food and water.
The formulations used for drug distribution studies were in situ gel and control, which were
administered via topical and subconjunctival route. The animals were divided into 4 groups
and the formulations were administered to the left eye of each animal and keeping the other
eye untreated. The study was conducted for 3 h on the animals treated with topical drops and
6 h for animals treated with subconjunctival injection. Topically, 50 µL of the formulations
were instilled into the cul-de-sac of left eye while for the subconjunctival route, 50 µL of the
formulations were injected accurately into the conjunctival membrane with tuberculin syringe
and 27-gauge needle. Around 15 minutes prior to injection, the rabbits were anaesthetized
13

with combination of ketamine and xylazine via intramuscular route. Approximately 5 µL of
tear fluid was pipetted out from the cul-de-sac of the test eyes using micro pipette at every 30
minutes for animals treated topically and at 60 minutes for animals treated with
subconjunctival injections. Approximately 10 minutes prior to the end time of the study, all
the animals were anaesthetized with same combination and were euthanized with
pentobarbital overdose via marginal ear vein. Both the test and untreated eyes were excised,
and washed with ice cold IPBS solution. The tissues were carefully isolated and were stored
at -80 °C until the drug extraction and quantification.

Extraction procedure of drug from ocular tissues
Drug extraction from the ocular tissues were carried out by protein precipitation
technique. Analysis for the drug content was performed on plasma, aqueous humor (AH),
vitreous humor (VH), cornea, iris-ciliary (IC), retinal choroid (RC), sclera and conjunctiva.
Individual weights of all the solid tissues were measured and later each tissues were minced
into small fragments and kept in separate vials. To all the tissues, the relevant amount of
triamcinolone acetonide with the concentration of 1 µg/mL (as internal standard) was added.
The vials were then vortexed thrice for 30 seconds each with the gap of 10 minutes between
each vortexing. Later, 1000 µL ice-cold methanol with 0.1% formic acid was added to each
vial and the process of vortexing was repeated. The samples were then centrifuged for 15
minutes at 13,000 rpm to separate out the precipitate, and the supernatant was then collected,
diluted if required and spiked in UPLC-triple quadrupole (TQ)-MS system for analysing the
concentration.
For liquid samples, 100 µL of plasma, 100 µL of AH and 500 µL of VH samples were
collected and similar extraction procedure was followed with 100 µL, 100 µL and 500 µL of
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ice-cold methanol was utilized for plasma, AH and VH respectively. After centrifuging for 15
minutes the samples were analyzed in UPLC-triple quadrupole (TQ)-MS system. The drug
content from the tear samples collected during the in vivo study was extracted using ice cold
methanol and analyzed in the same system.
For analysis of FA, Ultra-Performance Liquid Chromatography system coupled with a
triple quadrupole mass spectrometer (UPLC-TQ-MS) (Waters, USA), was utilized. The
quantification peaks of both the drug and the internal standard were obtained on the basis of
specific mass to charge (m/z) values of same.[24] 1 µL of the sample was eluted through
BEH C18 1.7 µm Acquity UPLC® column and separated using isocratic mode of ACN with
0.1% formic acid and water with 0.1% formic acid 1 µL of the sample was eluted at the ratio
of 98:2 respectively. The extraction efficiency, limit of detection and limit of quantification
of the drug was analyzed prior to drug concentration analysis.
For tear kinetics, from the concentration, the slope for the graph of time v/s
concentration was calculated which was further used to calculate time at which the
concentration of drug is half the initial concentration (t1/2) using the formula

𝒕𝟏/𝟐 =

𝟎. 𝟔𝟗𝟑
𝒔𝒍𝒐𝒑𝒆 ∗ −𝟐. 𝟑𝟎𝟑

Area under curve (AUC) for the plot was calculated using the formula

𝑨𝑼𝑪 = ∑[

(𝑪𝟏 + 𝑪𝟐)
∗ (𝒕𝟐 − 𝒕𝟏)]
𝟐

Where C1 and C2 are drug concentration in tear at time t1 and t2 respectively.
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Statistical analysis
Results were presented in their mean values ± standard deviation (SD). Statistical
analysis for in vitro permeation study and in vivo drug distribution study in ocular tissues was
done by One-way ANOVA (analysis of variance test) with Tukey’s post hoc test (R Studio
software, USA). The confidence interval set for the statistical analysis was 95% and hence
the p-value for the significant difference was less than 0.05 (p < 0.05).
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CHAPTER III
RESULTS AND DISCUSSION

Formulation development and optimization of FA-NLCs
Fluocinolone acetonide NLCs were formulated by hot homogenization along with
probe sonication. For formulating the NLCs, varied ratios of lipid to surfactant, and solid
lipid to liquid lipid and primary surfactant to secondary surfactants were considered.
Optimization of the formulation was determined based on the effect of these ratios on particle
size, ZP and drug content. All the ingredients utilized in the formulations are naturally
occurring and thus are biodegradable and the extent to which they were used in the
formulations were below the safety limits mentioned by FDA inactive ingredient limit.[25]
Selection of lipids whether solid or liquid and surfactant was based on the partitioning
behavior of the drug in respective component. Better the affinity, higher quantity of the drug
could be withholding within the formulation, thereby increasing both the percent drug content
and entrapped into the formulation. The selection of the lipid study shows that the drug had a
higher solubility towards didodecyldimethylammonium bromide, lauric acid, and compritol
888 ATO (Figure 1). Since compritol 888 ATO had shown the highest solubility i.e. 4.37
mg/g, hence, compritol 888 ATO was preferred over other as solid lipid for the development
of FA-NLC formulation.[20] Retiene, an aldehyde derivative of vitamin A has a fundamental
effect on the vision. Inadequacy in the content for vitamin A in the retina may progressively
lead to night blindness. Also, due to its low melting point (<30oC), vitamin A palmitate
provides more flexibility and imperfect crystallinity to the NLC structure, thus decreasing the
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drug leaching and also act as a permeation enhancer. Hence, vitamin A palmitate was
selected as solid lipid in combination with compritol 888 ATO for the formulation. Similarly,
in case of liquid lipids FA showed a higher affinity towards isopropyl myristate, miglyol and
sesame oil (Figure 1). However, because of its high physical compatibility and also due to its
natural origin, sesame oil was chosen over others as the liquid lipid component for the
preparation of FA-NLCs. The total lipid content in the formulation ranged from 1 to 2%
where higher lipid content contributes to high drug solubility.
Further, the selection of the surfactants was done based on the highest solubility of
FA in the surfactant solution. In general, a combination of the surfactants with the HLB range
from 4 to 7 (W/O emulsifiers) and with the HLB range from 8 to 18 (O/W emulsifiers) was
adopted for the preparation of NLCs were showed better stability.[26] From the solubility
results, a higher amount of FA solubility was observed with capmul PG 8, capryol 90, tween
80 and propylene glycol (Figure 1). Similarly, O/W surfactant that shows low solubility was
preferred as secondary surfactant for the formulation preparation. From the figure 1 we can
see that tween 80 and poly ethylene glycol 4000 had lowest solubility from all O/W
surfactants. Therefore, on the basis of their physical compatibility and formulation stability,
capmul PG 8 and tween 80 were selected as W/O and O/W emulsifiers for the preparation of
FA-NLC respectively.[12]
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Figure 1: Solubility of drug in various lipids and surfactants (mean±SD, n=3)

The proportion of the excipients utilized to formulate FA-NLCs were mentioned in
Table 1. For the development and optimization of the NLCs, various variables along with
their impact on characteristic features and stability of NLC were taken into consideration.[20]
These variables include different ratios of lipid to surfactant, solid to liquid lipid as well as
the ratio of W/O and O/W emulsifiers. Percent FA entrapped in all the formulation was in the
ranging of 60 to 97, with size and PDI in the range of approx. 160 to 270 nm and 0.15 to
0.52, respectively. The EE of the drug in all the formulations was greater than 91%, while the
charge for the most of the formulations falls in the range of -8 to -10 mV (Table 2).
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Table 2: Effect of lipid to surfactant and solid to liquid lipid ratio on size, PDI, ZP, EE and
assay of fluocinolone acetonide NLC formulations (mean±SD, n=3)

In the early stages of formulation development, the ratio of lipid to surfactant and
solid to liquid lipid was premeditated keeping the surfactant concentration constant and their
corresponding effect on particle size, PDI, and the assay were studied (Table 2). If the lipid to
surfactant ratio was 1:1, the particle size and PDI of the nanoparticles was found to be
considerably low in the range of 160 to 210 nm and responsible for better NLC formulation.
These results were observed in the formulations FN1, FN2, and FN3. However, increase in
the lipid content compared to surfactant concentration i.e., the ratio of 2:1 and 2:1.5, gave a
good particle size but distribution of the particles was more. These results exhibit that if the
amount of surfactant, when compared to lipid was less, distribution of the particles in the
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formulation increases. Similarly, the overall percent drug content of the FA-NLC scales down
to less than 90%, when the difference between the lipid and surfactant was higher. These
results were observed in FN4, FN5, FN7, FN8 and FN9 NLC formulations. The overall
reduction in PDI and drug content could be due to the measure of surfactant which was
adequate enough to form nanoparticulate emulsion, but inadequate to stabilize the same. This
can also be attributed to the surface charge of the formulations. Higher the difference
between lipids and surfactant features the surface charge more towards 0 which in turn leads
to more of instability. The ratio of solid to liquid lipid was determined on the basis of higher
drug solubility in lipid along with the suitable blend of solid and semi solid consistency of the
phase at room temperature. Since the solubility of FA was observed higher for solid lipids, a
higher proportion of solid lipid was favored in total lipid content. The preferable ratio
selected for formulation trials were from 70:30 to 90:10.[27] The evaluation results with
respect to different ratios of solid to liquid lipid ratio were mentioned in Table 2. It can be
inferred that relatively lower amount of sesame oil in the total lipid combination gave lower
assay values and when the ratio was other than 80:20, the PDI of the formulation was also
high. Therefore, in accordance with above assumption, the ratio of lipid to surfactant and
solid to liquid lipid was set as 1:1 and 80:20 respectively.

Table 3: Effect of O/W to W/O surfactant ratio on size, PDI, ZP, EE and assay of
fluocinolone acetonide NLC formulations (mean±SD, n=3)
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Both lipid to surfactant (1:1) and solid to liquid lipid (8:2) ratio are constant for all the
formulations. Formulation FN2b is same as formulation FN2 from table 2. Change in name of
formulation was done to have different representation in accordance with table 3.

After finalizing the quantity of lipids and total surfactant, formulation FN2 was
further evaluated for its characteristic features with various fraction of O/W and W/O
emulsifiers. From the Table 3, it can be presumed that size and PDI of nanoparticles with 1:1
ratio for capmul PG 8 and tween 80 was high and % entrapment was low compared to other
ratios. On the other hand, when the ratio of two surfactants was 1:3, the polydispersity of
formulation was high. When the ratio of O/W and W/O emulsifiers was taken as 1:2, the
average size, polydispersity index and assay of FA NLC was found to be 159.1 ± 3.8 nm,
0.150 ± 0.05, -8.4 ± 0.4, 96.53 ± 2.4 % and 95.43 ± 2.89 % respectively. The combination of
capmul PG 8 and tween 80 surfactants i.e. with the HLB value 6 and 15 exhibited excellent
NLC formulation possibly because capmul PG 8 (W/O surfactant) forms a layer around the
formed particles and tween 80 (O/W surfactant) stabilizes the formed particles with
surrounding aqueous phase by lowering the surface tension.[26] Therefore, formulation FN2b
was considered as optimized and selected for the preparation of in situ gel formulation.

Formulation development and optimization of FA-NLC in situ gels
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One of the critical quality attributes for in situ ophthalmic gel formulation is its flow
properties, as it helps to administer the formulation without any complication while
instillation into the ocular milieu. FA in situ gels was prepared by using various concentration
of gellan gum alone and combination with HPMC to provide ideal gelation along with
formulation’s rheological characteristic. Gellan gum is an anionic polysaccharide, which
forms a clear gel due to the presence of mono or divalent cations. An ideal viscosity for
ophthalmic solution ranges from 25-50 cP.[28] The concentration of gellan gum used and
their corresponding results on viscosity and other rheological characteristics of in situ gel
presented in Table 4. Since the viscosity of the formulation FN2G3 (0.3% of gellan gum) was
40.3 ± 1.8, gels immediately when in contact with STF and reside as gel for up to 6 h. Hence,
0.3% of gellan gum was selected as the optimum concentration for in situ gel formulation and
was used for the further analysis.
Methocel E5 is a neutral polymer which forms viscous solution by hydration of
hydrogen bonding in the polymer chains. Methocel E5 is a low molecular weight,
temperature sensitive polymer and increases the viscosity at around 35°C. The rheological
characteristic results of the formulation with varied concentrations of HPMC was presented
in Table 4. The viscosity of the formulation has been increased with increased concentration
of HPMC. The viscosity of the formulation holds in the ideal range for ophthalmic solution
even after addition of 0.5% concentration of HPMC to FN2G3 formulation owing to form
ideal in situ gelling system with higher viscosity value after addition to STF.[15], [16]
One of the major fall back for ophthalmic formulation is low inhabitancy in the cul de
sac. The gelling time of the formulation was determined so as to compute the time required
by in situ gelling formulation to form gel on contact with tear fluid. All the concentration of
gellan gum formulations (with and without HMPC) were observed to gel as soon as they
were added to the simulated fluid. The results of gelling time and gel residence time of in situ
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gels were specified in the Table 4. Firmness of the formulation was tested to analyze the
resistance of the gel to the external deformation and work of adhesion for the formulations
was done to analyze the adhesiveness of the gels when in contact with the tear fluid.[14], [29]
Firmness and work of adhesion for the formulation with 0.3% and 0.5% of gellan gum and
HPMC respectively with respect to time was showed in Figure 2. From the results, the values
for firmness and work of adhesion do not show significant variation even after 6 h,
suggesting the intactness of the gel for extended period of time (6 h). Therefore, in
accordance with the results and inference discussed in above sections, formulation FN2b and
FN2GH05 were considered as optimized FA-NLC and in situ gel formulation and were
chosen for the further studies.

Table 4: Rheological evaluation of fluocinolone acetonide NLC in situ gel formulations
(mean±SD, n=3)
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G and H indicates gellan gum and HPMC containing in situ gels respectively.
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Figure 2: Firmness (A) and work of adhesion (B) for in situ gels with respect to time
(mean±SD, n=3)

Stability studies of FA-NLC
The stability of FA-NLC formulation upon storage was evaluated by studying their physical
appearance and characteristics once a week for up to 4 weeks. Until 30 days, the formulation
did not show any sign of physical separation or breaking. The results for particle size, PDI,
assay and EE were shown in Figure 3. Further, the formulation was also tested for
postproduction sterility by moist heat sterilization. As per stability studies, the physical
aspects of the formulation did not exhibit any breaking or phase separation. It can be
determined that there was no significant change in any of the parameters tested. This could be
stating that the formulation was still intact after sterilization and also post 28 days of storage
without any phase separation or particle aggregation or drug oozing out of NLC gel.
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Figure 3: Stability studies of optimized FA-NLC and in situ gel at 4°C and 25 °C for 28
days, by autoclave on size and PDI (A), assay and entrapment efficiency (B) (mean±SD, n=3)

Compatibility studies - DSC and FTIR
The DSC thermograms of the FA and the physical mixture of the drug with lipid
phase is portrayed in Figure 4. The melting point of pure FA was found to be at around 270oC
as shown by evolution of a sharp endothermic peak corresponding to its reported melting
point. In case of lipid phase (including drug) DSC thermogram, there was a slight concavity
at around 55 to 60oC of compritol 888 ATO followed by constant heat flow up to 300oC.
This verifies the complete solubility and/or conversion of the drug in to amorphous form in
the lipid phase, as no separate endothermic peak was observed for the drug in NLC-lipid
phase thermogram.
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Figure 4: DSC thermograms of drug and NLC-Lipid phase

FTIR spectroscopy was performed for the drug and NLC to determine the potential
interaction between FA and lipid matrix throughout the formulation procedure. The FTIR
spectra for drug, lipid excipients and FA-NLC formulation is showed in Figure 5. For all the
spectras of lipid excipients and drug, the major bands were observed at around 1640 cmassigned to C=C, and around band 1728 cm- was assigned to C=O group. The bands from
2995 to 2952 cm- were assigned to C-H group. The NLC spectra exhibited the peak at 2916
cm- for C-H group and 1665 cm- for C=C. There was a slight spectral variation for NLC,
which might be due to overlapping of the similar functional group for various components.
However, there was no change in the band peaks for pure excipients and peaks in the NLC
spectra even in the presence of FA, indicating no substantial interaction between the drug and
excipients.
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Figure 5: FTIR spectra of the drug and NLC-Lipid phase and excipients

In vitro release study
Since the saturation solubility of FA was found to be maximum in BSS (pH 7.4) with
5% methyl- β- cyclodextrin. BSS solution was preferred as the receiver medium for in vitro
release and in vitro permeation studies.[30] The in vitro release profile of FA from control,
NLC, and in situ gel are presented in Figure 6. The cumulative release of the drug from
control, NLC, and in situ gel was found to be 102.34 ± 8.08, 46.62 ± 4.65, and 35.44 ± 4.39
% respectively within the period of 4 h. It could be due to the slow diffusion release from the
shell layer of lipid nanoparticles during the period of 4 h.
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Figure 6: In vitro drug release profiles of fluocinolone acetonide from control gel, FA-NLC
and in situ gel (mean±SD, n=3)

Turbidimetry measurement
The percent transmittance (%T), provide the extent of turbidity which could be the
extent of light obstruction during post injecting the formulation into the eye.[13] The
transmittance results for formulations over the period of 6 h are mentioned in Table 5. The %
transmittance for the in situ gel formulation was low due to cross-link formed by the gelling
agent in contact with STF. This indicates that, the gel link breaks with time with increase in
transmittance and thus releasing the formulation at the controlled rate.
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Table 5: Transmittance (%) of fluocinolone acetonide NLC and in situ gel formulation
(mean±SD, n=3)

Formulation

Transmittance (%)
0h

3h

6h

FA-NLC

35.08 ± 2.18

35.73 ± 3.21

38.11 ± 2.54

In situ gel

3.35 ± 0.71

15.35 ± 1.84

36.48 ± 4.47

In vitro permeability studies
The permeability of FA-NLC, in situ gel and control formulation were performed in
corneal and scleral tissues and the results presented in Figure 7. The tissue permeability of
PA form control, FA-NLC and in situ gel formulations were found to be 1.52 ± 0.2 x10-5
cm/s, 5.66 ± 0.18 x10-5 cm/s and 2.41 ± 0.08 x10-5 cm/s, respectively from corneal tissue
and 2.32 ± 0.14 x10-5 cm/s, 6.34 ± 0.1x10-5 cm/s, and 3.83 ± 0.21x10-5 cm/s, respectively
from scleral tissue. The flux values for control, FA-NLC and in situ gel formulations were
found to be 0.18 ± 0.02 μg/min/cm2, 0.68 ± 0.08 μg/min/cm2 and 0.29 ± 0.01 μg/min/cm2,
respectively for corneal tissue and 0.28 ± 0.02 μg/min/cm2, 0.76 ± 0.03 μg/min/cm2, and
0.46 ± 0.04 μg/min/cm2, respectively for scleral tissue. A significant increment in the tissue
permeability and flux was observed form both FA-NLC and in situ gel formulation compared
to the control formulation. The enhancement in permeability of FA form NLC and in situ gel
formulations in comparison to control might be due to lipophilicity of the formulation and
which imparts higher penetration through the tissues. Further, the lower flux of the drug from
in situ gel formulation compared to NLC formulation indicates the slow release of the drug
from in situ gel owing for controlled release. Furthermore, the drug permeability was higher
through the sclera compared to cornea, suggesting that non-corneal route may show better
drug penetration compared to the corneal route[1], [7], [12].
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* indicates the data for formulations is significant compared to control
Figure 7: In vitro permeability studies of fluocinolone acetonide from control suspension,
FA-NLC and in situ gel through ocular tissues (mean±SD, n=3)

In vivo tear kinetics and distribution study
In vivo distribution studies of FA from control and FA-NLC in situ gel formulations
was carried out in New Zealand albino rabbits treated by topical and subconjunctival
administration. The drug content was observed in rabbits treated with topical and
subconjunctival injection after 3h and 6h, respectively. The drug contents were estimated in
the tear after every 30 min for topically and every 60 min for subconjunctivally administered
formulations and were presented in the Table 6. From the results, it was observed that the
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highest concentration of the drug was observed at first 30 min (3.37 ± 2.10 µg/mL) with
topical and first 60 min (3.10 ± 0.20 µg/mL) with subconjunctivally administered
formulation. The half-life of FA from in situ formulation was found to be 3.22 h and 1.64 h
by subconjunctival injection and topical formulation. In case of ocular bioavailability, about
2.32 and 2.29-folds enhancement was observed with subconjunctival and topical
administration when compared with control gel. This could be due to the diffusion release of
the drug from the lipid nanoparticles into the tear and then its permeation through the cornea.
As evident from the Table 5, the rate of drug expulsion from NLC in situ gel was predicted to
be a sustained release, as the concentration of the drug in tear decreased gradually compared
to the control formulation. Thus, the tear kinetic analysis clearly explains the release pattern
of the drug for different formulations.[31]

Table 6: In vivo tear kinetics for fluocinolone acetonide from in situ gel formulation and
control in New Zealand albino rabbits (mean±SD, n=3).

For subconjunctival formulations 0, 1, 2, 3, 4, 5 and 6 represents 0 min, 60 min, 120 min, 180
min, 240 min, 300 min and 360 min respectively and for topical formulations 0, 1, 2, 3, 4, 5
and 6 represents 0 min, 30 min, 60 min, 90 min, 120 min, 150 min and 180 min respectively
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The concentration levels of FA from in situ gel and control formulation in aqueous
humor (AH), vitreous humor (VH), cornea, iris ciliary (IC), retinal choroid (RC) and scleral
tissues after topical and subconjunctival administration are showed in Table 7 and Figure 8.
From the results, the drug concentration in the aqueous humor and vitreous humor were
determined to be 0.016 ± 0.00 µg/mL and 0.005 ± 0.01 µg/mL for control formulation and
0.021 ± 0.01 µg/mL and 0.008 ± 0.01 µg/mL respectively for in situ gel by topical
administration (Figure 8a). The high concentration of drug was observed in cornea and IC
after 3 h post administration and thereby explaining the effectiveness of the in situ gel system
in ocular tissues. Additionally, significantly high concentration of the drug was observed in
scleral and RC tissues (p value < 0.05), suggesting high drug permeability from our novel in
situ gel system in the posterior ocular compartment. Hence, enhancing the release kinetics of
the drug in ocular tissue.[5], [32]

Table 7: In vivo fluocinolone acetonide distribution in ocular tissues from in situ gel
formulation in New Zealand albino rabbits (mean±SD, n=3).

* indicates the value is statistically significant compared to control for same route.
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* indicates the value is statistically significant compared to control for same route.
Figure 8: in vivo fluocinolone acetonide distribution in ocular tissues (A) Topical
formulation (B) Subconjunctival formulation (mean±SD, n=3).

For subconjunctival injection, considerably high concentration of the drug was
observed in sclera and RC when treated with in situ gel compared to control formulation. The
concentration of drug in AH, cornea, IC, sclera and RC were 0.021 ± 0.01 µg/mL, 4.87 ±
3.64 µg/g, 0.51 ± 0.03 µg/g, 43.81 ± 27.71 µg/g, 12.44 ± 4.60 µg/g and 0.003 ± 0.00 µg/mL,
1.42 ± 0.15 µg/g, 0.28 ± 0.13 µg/g, 11.12 ± 0.65 µg/g and 5.24 ± 3.78 µg/g, respectively from
in situ gel and control gel, which was significantly higher. Thus, it can be presumed that the
drug permeation into the ocular tissue follows both corneal and non-corneal route. Due to the
depot formation in conjunctiva, there is controlled and simultaneous drug release from the
NLC into cornea and sclera since the tissue is in direct contact with cornea and sclera. The
drug concentration in sclera and RC were calculated to be approximately 3.93 and 2.37-folds
compared to control subconjunctival injection. Compared to the topical in situ gel, drug
concentration in the ocular tissues for subconjunctival formulations were 3.0, 4.23, 1.88,
14.63 and 76.87 folds for VH, cornea, IC, RC and sclera respectively. The superlative levels
of drug content in all the tissues shows the high-caliber for subconjunctival administration
compared to topical administration. However, compared to posterior section, the amount of
drug in the anterior section of the eye was considerably low. This was suggesting that the
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drug flow route is notably towards the posterior end of the eye. Drug concentration were also
analyzed in the conjunctival tissue post 6 h of study. The amount of the drug in conjunctiva
was found to be 31 µg/mL (with the average weight of tissue of 107 mg). Thus, a higher drug
level in the posterior section of the ocular tissues even after 6 h post injection suggest the
extended release rates of the drug from the in situ gel system there by proving the
translational ability of these formulation to clinics.[1], [19]
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CHAPTER IV
CONCLUSION

In this study, fluocinolone acetonide NLC in situ gels were successfully formulated
with vitamin A as one of the lipid by hot homogenization coupled with probe sonication
method. The formulation had excellent particle size distribution (159) and PDI (0.150). The
assay and drug entrapment were more than 94% with excellent stability for the period of up
to four weeks. The stable in situ gel formulated with gellan gum and HPMC showed higher in
vitro tissue permeation and high drug concentration at posterior end of the ocular tissues
when administered as subconjunctival injection. Thus exhibiting suitability of these carrier
systems for prolong ocular pharmacotherapy.
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